Phase I/Ib clinical trial of PM54 in Advance Solid Tumors patients

2023-508644-22-00 Phase I and Phase II (Integrated) - First administration to humans Ongoing, recruiting

Start 28 Feb 2023 · Status Ongoing, recruiting · 3 EU/EEA countries · 14 sites

Overview

Sponsor-declared trial summary

Phase Phase I and Phase II (Integrated) - First administration to humans
Status Ongoing, recruiting
Participants planned 110
Countries 3
Sites 14

Advance Solid Tumors

Key facts

Sponsor
Pharma Mar S.A.
Participant type
Patients
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Neoplasms [C04]
Trial duration
28 Feb 2023 → ongoing
Decision date (initial)
2023-12-05
Transition trial
Yes
Low-intervention
No
Rare-disease indication
No
Vulnerable population
Yes

External identifiers

EU CT number
2023-508644-22-00
EudraCT number
2022-002031-65
ClinicalTrials.gov
NCT05841563

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Advance Solid Tumors

VersionLevelCodeTermSystem organ class
20.0 LLT 10007050 Cancer 10029104

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Pharma Mar S.A.

Sponsor organisation
Pharma Mar S.A.
Address
Avenida De Los Reyes 1, Poligono Industrial La Mina Poligono Industrial La Mina
City
Colmenar Viejo
Postcode
28770
Country
Spain

Scientific contact point

Organisation
Pharma Mar S.A.
Contact name
Chelo Tudela

Public contact point

Organisation
Pharma Mar S.A.
Contact name
Chelo Tudela

Locations

3 EU/EEA countries · 14 investigational sites

By country

CountryMS statusPlanned subjectsSites
Belgium Ongoing, recruiting 35 3
France Ongoing, recruiting 15 3
Spain Ongoing, recruiting 35 8
Rest of world
United States
25

Investigational sites

Belgium

3 sites · Ongoing, recruiting
Grand Hopital De Charleroi
Medical Oncology, Rue Du Campus Des Viviers 1, 6060, Charleroi
Universitair Ziekenhuis Antwerpen
Medical Oncology, Drie Eikenstraat 655, 2650, Edegem
Institut Jules Bordet
Clinical Trial Conduct Unit, Mijlenmeersstraat 90, 1070, Anderlecht

France

3 sites · Ongoing, recruiting
Assistance Publique Hopitaux De Paris
Oncology, 27 Rue Du Faubourg Saint Jacques, 75014, Paris
Centre Hospitalier Regional De Marseille
Oncology, 265 Chemin Des Bourrely, 13015, Marseille
Institut Paoli Calmettes
Oncology, 232 Boulevard De Sainte Marguerite, Bp 156, Marseille

Spain

8 sites · Ongoing, recruiting
Hospital Universitari Vall D Hebron
Oncology, Passeig De La Vall D'Hebron 119-129, 08035, Barcelona
Hospital Universitario Y Politecnico La Fe
Oncology, Avenida De Fernando Abril Martorell 106, 46026, Valencia
Hospital San Pedro
Oncology, Calle Piqueras 98, 26006, Logrono
Hospital Universitario 12 De Octubre
Oncology, Avenida De Cordoba Sn, 28041, Madrid
NEXT Oncology Barcelona - Hospital Quiron Salud Barcelona
Oncology, Plaza Alfonso Comín 5-7, 08023, Barcelona
Hospital Universitario Ramon Y Cajal
Oncology, Carretera Del Colmenar Viejo Km 9 100, Por El Pardo, Madrid
Hospital Universitario Hm Sanchinarro
Oncology, Calle Ona 10, 28050, Madrid
Hospital Universitario Quironsalud Madrid
Oncology, Calle De Diego De Velazquez 1, 28223, Pozuelo De Alarcon

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Belgium 2023-06-14 2023-07-20
France 2025-12-22 2026-04-13
Spain 2023-02-28 2023-03-24

Application history

14 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2023-10-23 Spain Acceptable
2023-11-14
2023-11-14
2 SUBSTANTIAL MODIFICATION SM-1 2024-02-20 Spain Acceptable
2024-04-22
2024-04-22
3 SUBSTANTIAL MODIFICATION SM-2 2024-06-26 Spain Acceptable
2024-08-05
2024-08-07
4 SUBSTANTIAL MODIFICATION SM-3 2024-10-11 Spain Acceptable 2024-10-28
5 SUBSEQUENT ADDITION OF MSC APP-5 2024-10-25 Acceptable
2024-08-05
2025-01-15
6 SUBSTANTIAL MODIFICATION SM-4 2024-11-21 Acceptable 2024-12-18
7 NON SUBSTANTIAL MODIFICATION NSM-1 2025-02-14 Spain Acceptable 2025-02-14
8 SUBSTANTIAL MODIFICATION SM-6 2025-04-14 Spain Acceptable
2025-05-29
2025-05-29
9 SUBSTANTIAL MODIFICATION SM-7 2025-07-10 Spain Acceptable
2025-08-19
2025-08-22
10 SUBSTANTIAL MODIFICATION SM-8 2025-09-24 Acceptable 2025-10-21
11 SUBSTANTIAL MODIFICATION SM-9 2025-09-24 Acceptable 2025-10-24
12 SUBSTANTIAL MODIFICATION SM-10 2025-09-30 Spain Acceptable 2025-10-27
13 SUBSTANTIAL MODIFICATION SM-11 2026-01-22 Spain Acceptable
2026-05-04
2026-05-05
14 NON SUBSTANTIAL MODIFICATION NSM-2 2026-05-22 Spain Acceptable
2026-05-04
2026-05-22